0
Controversies in Internal Medicine |

Benefits of Combination Therapy of Insulin and Oral Hypoglycemic Agents

Alan J. Garber, MD, PhD
Arch Intern Med. 2003;163(15):1781-1782. doi:10.1001/archinte.163.15.1781.
Text Size: A A A
Published online

Extract

IN THE 40 years since their introduction, oral hypoglycemic agents have become the cornerstone of pharmacologic therapy in type 2 diabetes mellitus. The 5 classes of oral agents now available are sulfonylureas, meglitinides, thiazolidinediones, biguanides, and α-glucosidase inhibitors. However, initial therapy with any of these agents ultimately fails as the result of a gradual loss of β-cell insulin secretory response to glucose. Treatment with an oral agent is often initiated as monotherapy; as glycemic control progressively worsens, a second agent is added in combination. The reported failure rates for single oral agents—5% to 20% per year—suggest that single oral therapy in type 2 diabetes succeeds for approximately 5 years. When therapy with multiple oral agents fails, exogenous insulin is required and is usually added to 1 or more of the existing regimen of oral agents. A large body of evidence suggests that insulin therapy should be initiated earlier in diabetes treatment and in combination with an oral agent to restore and maintain glycemic control, thus possibly reducing comorbidities of diabetes and sparing the remaining β-cell function.1

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 14

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();